Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : Researchers at Novartis Report New Data on Medicinal Chemistry [Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:24pm CEST

Researchers at Novartis Report New Data on Medicinal Chemistry [Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors]

By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Health and Medicine - Medicinal Chemistry are presented in a new report. According to news reporting out of Basel, Switzerland, by NewsRx editors, research stated, "The predominant expression of phosphoinositide 3-kinase d (PI3Kd) in leukocytes and its critical role in B and T cell functions led to the hypothesis that selective inhibitors of this isoform would have potential as therapeutics for the treatment of allergic and inflammatory disease. Targeting specifically PI3Kd should avoid potential side effects associated with the ubiquitously expressed PI3Ka and b isoforms."

Our news journalists obtained a quote from the research from Novartis, "We disclose how morphing the heterocyclic core of previously discovered 4,6-diaryl quinazolines to a significantly less lipophilic 5,6,7,8-tetrahydropyrido[4,3-]pyrimidine, followed by replacement of one of the phenyl groups with a pyrrolidine-3-amine, led to a compound series with an optimal on-target profile and good ADME properties. A final lipophilicity adjustment led to the discovery of CDZ173 (leniolisib), a potent PI3Kd selective inhibitor with suitable properties and efficacy for clinical development as an anti-inflammatory therapeutic. , CDZ173 inhibits a large spectrum of immune cell functions, as demonstrated in B and T cells, neutrophils, monocytes, basophils, plasmocytoid dendritic cells, and mast cells. , CDZ173 inhibits B cell activation in rats and monkeys in a concentration-and time-dependent manner. After prophylactic or therapeutic dosing, CDZ173 potently inhibited antigen-specific antibody production and reduced disease symptoms in a rat collagen-induced arthritis model. Structurally, CDZ173 differs significantly from the first generation of PI3Kd and PI3Kgd-selective clinical compounds. Therefore, CDZ173 could differentiate by a more favorable safety profile."

According to the news editors, the research concluded: "CDZ173 is currently in clinical studies in patients suffering from primary Sj?gren's syndrome and in APDS/PASLI, a disease caused by gain-of-function mutations of PI3Kd."

For more information on this research see: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. Acs Medicinal Chemistry Letters, 2017;8(9):975-980. (American Chemical Society - www.acs.org; Acs Medicinal Chemistry Letters - www.pubs.acs.org/journal/amclct)

Our news journalists report that additional information may be obtained by contacting K. Hoegenauer, Global Discovery Chemistry, PK Sciences, Chemical Biology and Therapeutics and Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland. Additional authors for this research include N. Soldermann, F. Zecri, R.S. Strang, N. Graveleau, R.M. Wolf, N.G. Cooke, A.B. Smith, G.J. Hollingworth, J. Blanz, S. Gutmann, G. Rummel, A. Littlewood-Evans and C. Burkhart (see also Health and Medicine - Medicinal Chemistry).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acsmedchemlett.7b00293. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Basel, Europe, Switzerland, Health and Medicine, Medicinal Chemistry.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
07/21NOVARTIS : and Sandoz Recall Non-Compliant Blister Packs
07/21MorphoSys, Galapagos ink global license pact with Novartis Pharma to develop ..
07/20Swiss, German drugmakers join U.S. price freeze
07/20NOVARTIS : Adlai Nortye Announce Global License Agreement for Buparlisib BKM120
07/20NOVARTIS : Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, ..
07/20NOVARTIS AG : Free Post Earnings Research Report: Novartis’ Net Sales Jumped 7%;..
07/20NOVARTIS : Patent Issued for Prostaglandin Conjugates and Derivatives for Treati..
07/20AEQUUS PHARMACEUTICALS : Extends and Enhances Commercial Agreement to Promote Vi..
07/20NOVARTIS : New Asthma Findings Reported from Novartis (Description of Baseline C..
07/20NOVARTIS : Patent Issued for Ophthalmic Illumination Profiles and Associated Dev..
More news
News from SeekingAlpha
07/20Allergan holds off Novartis' generic version of Combigan 
07/203 THINGS IN BIOTECH, JULY 20 : The Specter Haunts This Small Biotech 
07/20MUSTANG BIO : A Differentiated CAR-T Innovator With Multiple Unlocking Catalysts 
07/20Allergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To .. 
07/19Galapagos and MorphoSys out-license MOR106 to Novartis for up to $1.1B 
Financials ($)
Sales 2018 52 272 M
EBIT 2018 12 876 M
Net income 2018 9 727 M
Debt 2018 13 886 M
Yield 2018 3,56%
P/E ratio 2018 16,47
P/E ratio 2019 20,39
EV / Sales 2018 4,22x
EV / Sales 2019 4,06x
Capitalization 207 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 90,0 $
Spread / Average Target 8,7%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-1.75%206 705
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171
AMGEN9.54%126 889